메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

TraceLink Recognized on Fast Company's Next Big Things…

The annual list honors groundbreaking advancements redefining the way we work and live BOSTON, Oct. 20, 2025 -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced its inclusion in Fast Company's Next Big Things in Tech list in the Enduring Impact category. This prestigious recognition highlights emerging technologies that have the potential to profoundly impact industries—from education and sustainability to robotics and artificial intelligence. The Enduring Impact category honors tech breakthroughs from
- 김갑성 기자
- 2025-10-20 23:59
WellsCare Partners with Celltrion Canada to Bring Advanced W…

SEOUL, South Korea, Oct. 20, 2025 -- WellsCare, a South Korean medical technology startup, announced that on October 9, it signed a Memorandum of Understanding (MOU) with Celltrion Canada, a subsidiary of the global biopharmaceutical leader Celltrion. This strategic partnership is set to enhance the development and distribution of advanced laser medical devices for pain management across North America. The collaboration will focus on the distribution of WellsCare's innovative home-use laser therapy device, IASO, which is designed for effective musculoskeletal pain relief. The I
- 김갑성 기자
- 2025-10-20 21:00
BTL's EMSCULPT NEO Used in Astronaut Training in Hungary fo…

PRAGUE, Oct. 20, 2025 -- BTL, a global leader in medical technologies, proudly announces that its flagship device, EMSCULPT NEO, played a key role in astronaut preparation ahead of a historic spaceflight. As a result of the cooperation between BTL Hungary and HUNOR (Hungarian To Orbit) program, EMSCULPT NEO was incorporated into Hungarian research astronaut Tibor Kapu's intensive pre-flight training program to prepare for his upcoming mission aboard the International Space Station (ISS). "Studies show astronauts lose up to 30% of muscle mass in or
- 김갑성 기자
- 2025-10-20 20:09
Weaving a Network of Care Together: Jiahui International Hos…

SHANGHAI, Oct. 20, 2025 -- On the morning of Oct. 18, 2025, during Jiahui Health's Breast Cancer Awareness Month program, Jiahui International Hospital (Shanghai) was officially recognized as an internship site for the Social Work program at NYU Shanghai. John K. HSIANG, MD, PhD, chairman of the Jiahui Health Executive Committee, and Qingwen Xu, coordinator of the Global MSW Program and affiliated professor at NYU Shanghai, and professor of social work at NYU's Silver School of Social Work, unveiled the plaque. Nearly one hundred medical professionals and patients' families witnessed this mil
- 김갑성 기자
- 2025-10-20 20:03
Exploring the Next Era of Cell & Gene Therapy with Nobel Laure…

PISCATAWAY, N.J., Oct. 20, 2025 -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of the fastest-growing fields in emerging medicine. CGT is rapidly transforming the landscape of modern medicine, driving breakthroughs from laboratory research into real-world clinical applications. From genome editing to in vivo and ex vivo cell therapy platforms, CGT has become one of the most promising fields in life sciences, supported by rising global
- 김갑성 기자
- 2025-10-20 19:43
ST Engineering iDirect Announces General Availability of Intu…

Cloud-native architecture and high-density baseband processing improves operational efficiency, performance and TCO HERNDON, Va., Oct. 20, 2025 -- ST Engineering iDirect, a global leader in satellite communications, today announced the general availability of Intuition 1.1, its next-generation ground system. Built on cloud-native, multi-orbit architecture, this release introduces advanced capabilities designed to unify satellite operations, enhance adaptability and maximize efficiency. The foundation of Intuition is its efficient, cloud-native architecture, which reduces
- 김갑성 기자
- 2025-10-20 19:00
HanchorBio Showcases Pipeline Momentum with HCB101 and…

[ 메디채널 김갑성 기자 ] Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that new clinical data from HCB101, its differentiated, engineered SIRPα-Fc fusion protein, and the preclinical results from HCB301, its next-generation tri-specific checkpoint immunotherapy, will be present
- 김갑성 기자
- 2025-10-20 19:00
Groundbreaking Study in the Journal of Clinical Investigation…

SHANGHAI, Oct. 20, 2025 -- The research team led by Dr. Yuejun Chen, founder of UniXell Biotech, published online an article titled "3D-Cultured Human Medium Spiny Neurons Achieve Functional Integration into Huntingtin Disease Mouse Neural Circuits and Improve Motor Deficits" in the Journal of Clinical Investigation, collaborating closely with Xiong Lab at Fudan University, Shanghai. This study presents a method for generating authentic medium spiny neurons (MSNs) and provides comprehensive mechanistic insights that underpin cell-replacement therapy for Huntington's disease.
- 김갑성 기자
- 2025-10-20 18:13
The New England Journal of Medicine Publishes Results of…

After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). OS was significantly longer with sac-TMT than with chemotherapy (HR, 0.60; 95% CI, 0.44 to 0.82; two-sided P=0.001); 18-month OS rate was 65.8% and 48.0%, respectively. In the supplementary analysis, in which data were censored at the start date of subsequent ADC, the HR was 0.56 (95% CI, 0.41 to 0.77). Sac-TMT was associated with a higher incidence of sto
- 김갑성 기자
- 2025-10-20 17:06
ESMO Congress 2025 Presidential Symposium Oral Presentation…

BERLIN, Oct. 20, 2025 -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by RemeGen Co., Ltd. was presented at the Presidential Symposium by Professor Jun Guo from Beijing Cancer Hospital. It's the first time a research led by Chinese scholars in the field of urological oncology has ever been selected in this honorable session. The full manuscript was simultaneously
- 김갑성 기자
- 2025-10-20 14:58

이전

61 62 63 64 65 66 67 68 69 70

많이 본 기사

최근기사

2025-12-13_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 13일 23시 40분